Results per Page:
New cell products can improve cord blood transplant outcomes
From Dr. Filippo Milano and colleagues, Translational Sciences and Therapeutics Division
Umbilical cord blood transplant with pooled stem cell product shows 96% survival and no graft-versus-host-disease in leukemia patients
A phase 2 study published in the Journal of Clinical Oncology shows that a stem cell product called dilanubicel safely enabled umbilical cord blood transplants in 28 patients
Dr. Filippo Milano receives inaugural Endowed Chair in Cord Blood Research
Unrestricted funding will help grow Fred Hutch’s Cord Blood Transplant Program so that ‘every patient has a donor’
Novel regimen greatly reduced chronic GVHD in phase 2 study at Fred Hutch
Substituting cyclophosphamide for a standard post-transplant immunosuppressant is a “gamechanger”